Frazier Life Sciences Management, L.P.
PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$4.03B2026 Q3
Positions44
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.70.8%
What Changed This Quarter?
Top Holdings
MIRM
Mirum Pharmaceuticals
16.3%
NAMS
NewAmsterdam Pharma Co
11.5%
ERAS
Erasca
10.7%
MBX
MBX Biosciences
9.7%
ARQT
Arcutis Biotherapeutics
6.5%
MAZE
Maze Therapeutics
3.6%
TRVI
Trevi Therapeutics
3.4%
KRYS
Krystal Biotech
3.2%
New / Increased
7 new · 10 increased
ATTONEW
Attovia Therapeutics
3.0%
BRVENEW
Braveheart Bio
2.6%
ASNDNEW
Ascendis Pharma A/S
1.3%
CLDXNEW
Celldex Therapeutics
0.7%
SRPTNEW
Sarepta Therapeutics
0.5%
ERAS
Erasca
10.7%
+18.0%
MNKD
Mannkind
1.5%
+138.7%
NAMS
Newamsterdam Pharma
11.5%
+5.0%
Reduced / Exited
5 reduced · 4 sold out
SVRA
Savara
0.1%
-88.5%
KRYS
Krystal Biotech
3.2%
-18.7%
IRON
Disc Medicine
1.5%
-31.0%
TRVI
Trevi Therapeutics
3.4%
-4.0%
TARS
Tarsus Pharmaceuticals
1.4%
-1.1%
BBIOEXIT
Bridgebio Pharma
2.5%
CYTKEXIT
Cytokinetics
2.2%
Ascendis Phar…EXIT
Ascendis Pharma A/S
1.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.